These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30041763)

  • 41. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Du RC; Ouyang YB; Lu NH; Hu Y
    Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y; Yue L; Hu W
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
    Lyu QJ; Pu QH; Zhong XF; Zhang J
    Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variables influencing outcome of Helicobacter pylori eradication therapy in South China.
    Cai W; Zhou L; Ren W; Deng L; Yu M
    Helicobacter; 2009 Oct; 14(5):91-6. PubMed ID: 19751433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
    Liu L; Nahata MC
    Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea.
    Lee JW; Kim N; Kim JM; Nam RH; Kim JY; Lee JY; Lee DH; Jung HC
    Scand J Gastroenterol; 2014 Aug; 49(8):917-24. PubMed ID: 24988873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
    Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Ju KP; Kong QZ; Li YY; Li YQ
    Helicobacter; 2024; 29(1):e13054. PubMed ID: 38900537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates.
    Huh CW; Youn YH; Jung da H; Park JJ; Kim JH; Park H
    PLoS One; 2016; 11(9):e0162258. PubMed ID: 27588679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
    Hu Y; Xu X; Ouyang YB; He C; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Lu NH; Zhu Y
    Helicobacter; 2022 Oct; 27(5):e12923. PubMed ID: 36036087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.